Fundraising FoxPortfolia — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Lighthouse Pharmalighthousepharma.cominApr 2026
Lighthouse Pharmaceuticals develops precision therapeutics for major unmet medical needs, with a lead program (LHP588), a gingipain inhibitor being tested in the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease.
BiotechLongevityNovato, US
Casey Lynch(Executive Officer, Director, Promoter)inStephen Dominy(Director)
BoardCampbell Murray(Director)in
Co-investorsMSIVMarin Sonoma Impact Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.